Biological activity of dihydroartemisinin in canine osteosarcoma cell lines

American Journal of Veterinary Research

Volumn 69, Issue 4, 2008, Pages 519-526

  Hosoya, Kenji ^a   Murahari, Sridhar ^a   Laio, Albert ^a,b   London, Cheryl A ^a   Couto, C Guillermo ^a   Kisseberth, William C ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b DEPARTMENT OF HEALTH   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

2,7 BIS(CARBOXYETHYL) 6 CARBOXYFLUORESCEIN; CASPASE 3; DIHYDROARTEMISININ; PROPIDIUM IODIDE; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; CANCER CELL CULTURE; CELL ASSAY; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL VIABILITY; DNA FRAGMENTATION; DOG DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; MALE; NONHUMAN; OSTEOSARCOMA CELL; STAINING; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARTEMISININS; BLOTTING, WESTERN; BONE NEOPLASMS; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DNA FRAGMENTATION; DOG DISEASES; DOGS; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; INHIBITORY CONCENTRATION 50; OSTEOSARCOMA; REACTIVE OXYGEN SPECIES; SESQUITERPENES;

CANIS FAMILIARIS;

EID: 42349085793     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.69.4.519     Document Type: Article

References (35)

1. Nosten F, Price RN. New antimalarials: a risk-benefit analysis. Drug Saf 1995;12:264-273.
2. Jiang JB, Li GQ, Guo XB, et al. Antimalarial activity of mefloquine and qinghaosu. Lancet 1982;2:285-288.
3. Posner GH, Cumming JN, Krasavin M. Carbon-centered radicals and rational design of new antimalarial peroxide drugs. In: Torrence PF, ed. Biomedial chemistry: applying chemical principles to the understanding and treatment of disease. New York: John Wiley & Sons, 2000; 289-309.
4. Meshnick SR. Artemisinin antimalarials: mechanisms of action and resistance. Med Trop (Mars) 1998;58(suppl 3):13-17.
5. Woerdenbag HJ, Moskal TA, Pras N, et al. Cytotoxicity of ar-temisinin-related endoperoxides to Ehrlich ascites tumor cells. J Nat Prod 1993;56:849-856.
6. Efferth T, Rucker G, Falkenberg M, et al. Detection of apoptosis in KG-1a leukemic cells treated with investigational drugs. Arzneimittelforschung 1996;46:196-200.
7. Efferth T, Dustan H, Sauerbrey A, et al. The antimalarial artesunate is also active against cancer. Int J Oncol 2001;18:767-773.
8. Singh NP Lai H. Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sci 2001;70:49-56.
9. Efferth T, Sauerbrey A, Olbrich A, et al. Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol 2003;64:382-394.
10. Singh NP, Lai H. Artemisinin induces apoptosis in human cancer cells. Anticancer Res 2004;24:2277-2280.
11. May WS, Cuatrecasas P. Transferrin receptor: its biological significance. J Membr Biol 1985;88:205-215.
12. Lai H, Singh NP. Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin. Cancer Lett 1995;91:41-46.
13. Lai H, Sasaki T, Singh NP et al. Effects of arteminisin-tagged holotransferrin on cancer cells. Life Sci 2005;76:1267-1279.
14. Efferth T, Benakis A, Romero MR. Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic Biol Med 2004;37:998-1009.
15. Nam W, Tak J, Ryu JK, et al. Effects of artemisinin and its derivatives on growth inhibition and apoptosis of oral cancer cells. Head Neck 2007;29:335-340.
16. Paik IH, Xie S, Shapiro TA, et al. Second generation, orally active, antimalarial, artemisinin-derived trioxane dimers with high stability, efficacy, and anticancer activity. J Med Chem 2006;49:2731-2734.
17. Efferth T, Olbrich A, Bauer R. mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether. Biochem Pharmacol 2002;64:617-623.
18. Zheng GQ. Cytotoxic terpenoids and flavonoids from Artemisia annua. Planta Med 1994;60:54-57.
19. Beekman AC, Wierenga PK, Woerdenbag HJ, et al. Artemisinin-derived sesquiterpene lactones as potential antitumour compounds: cytotoxic action against bone marrow and tumour cells. Planta Med 1998;64:615-619.
20. Posner GH, Ploypradith P, Parker MH, et al. Antimalarial, antiproliferative, and antitumor activities of artemisinin-derived chemically robust, trioxane dimmers. J Med Chem 1999;42:4275-4280.
21. Moore JC, Lai H, Li JR, et al. Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat. Cancer Lett 1995;98:83-87.
22. Singh NP, Cerma KB. Case report of a laryngeal squamous cell carcinoma treated with artesunate. Archive Oncol 2002;10:279-280.
23. Berger TG, Dieckmann D, Efferth T, et al. Artesunate in the treatment of metastatic uveal melanoma: first experiences. Oncol Rep 2005;14:1599-1603.
24. Singh NP, Panwar VK. Case report of a pituitary macroadenoma treated with artemether. Integr Cancer Ther 2006;5:391-394.
25. Lai H, Singh NP Oral artemisinin prevents and delays the development of 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast cancer in the rat. Cancer Lett 2006;231:43-48.
26. Disbrow GL, Baege AC, Kierpiec KA, et al. Dihydroartemisinin is cytotoxic to papillomavirus-expressing epithelial cells in vitro and in vivo. Cancer Res 2005;65:10854-10861.
27. Mukanganyama S, Widersten M, Naik YS, et al. inhibition of glutathione S-transferases by antimalarial drugs possible implications for circumventing anticancer drug resistance. Int J Cancer 2002;97:700-705.
28. Reungpatthanaphong P, Mankhetkom S. Modulation of multidrug resistance by artemisinin, artesunate and dihydroartemisinin in K562/adr and GLC4/adr resistant cell lines. Biol Pharm Bull 2002;25:1555-1561.
29. Kim SJ, Kim SM, Lee JW, et al. Dihydroartemisinin enhances radiosensitivity of human glioma cells in vitro. J Cancer Res Clin Oncol 2006;132:129-135.
30. Meshnick SR. Artemisinin: mechanisms of action, resistance and toxicity. Int J Parasitol 2002;32:1655-1660.
31. Renschler MF. The emerging role of reactive oxygen species in cancer therapy. Eur J Cancer 2004;40:1934-1940.
32. Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 2004;7:97-110.
33. Ruefli AA, Ausserlechner MJ, Bernhard D, et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoyl-anilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 2001;98:10833-10838.
34. Newton PN, van Vugt M, Teja-Isavadharm P, et al. Comparison of oral artesunate and dihydroartemisinin antimalarial bioavailabilities in acute falciparum malaria. Antimicrob Agents Chemother 2002;46:1125-1127.
35. China Cooperative Research Group on qinghaosu and its derivatives as antimalarials. Studies on the toxicity of qinghaosu and its derivatives. J Tradit Chin Med 1982;2:31-38.